Home / 2021 / January / 07

Daily Archives: January 7, 2021

Constellation Brands Reports Third Quarter Fiscal 2021 Results

VICTOR, N.Y., Jan. 07, 2021 (GLOBE NEWSWIRE) — Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, reported today its third quarter fiscal 2021 results. A conference call to discuss the financial results and outlook will be hosted by President and Chief Executive Officer Bill Newlands and Chief Financial Officer Garth Hankinson on Thursday, January 7, 2021 at 11:30 a.m. (EST).

Visit cbrands.com/investors/events to locate information for joining the conference call, or a live, listen-only webcast of the conference call.

ABOUT CONSTELLATION BRANDS
At Constellation Brands (NYSE: STZ and STZ.B), our mission is to build brands that people love because we believe sharing a toast, unwinding after a day, celebrating milestones, and helping people connect, are Worth Reaching For. It’s worth our dedication, hard work, and the bold calculated risks we take to deliver more for our consumers, trade partners, shareholders, and communities in which we live and work. It’s what has made us one of the fastest-growing large CPG companies in the U.S. at retail, and it drives our pursuit to deliver what’s next.

Today, we are a leading international producer and marketer of beer, wine, and spirits with operations in the U.S., Mexico, New Zealand, and Italy. Every day, people reach for our high-end, iconic imported beer brands such as Corona Extra, Corona Light, Corona Premier, Modelo Especial, Modelo Negra, and Pacifico, and our high-quality premium wine and spirits brands, including the Robert Mondavi Brand Family, Kim Crawford, Meiomi, The Prisoner Brand Family, SVEDKA Vodka, Casa Noble Tequila, and High West Whiskey.

But we won’t stop here. Our visionary leadership team and passionate employees from barrel room to boardroom are reaching for the next level, to explore the boundaries of the beverage alcohol industry and beyond. Join us in discovering what’s Worth Reaching For.

To learn more, follow us on Twitter @cbrands and visit www.cbrands.com.

MEDIA CONTACTS INVESTOR RELATIONS CONTACTS
Mike McGrew 773-251-4934 / michael.mcgrew@cbrands.com
Amy Martin 585-678-7141 / amy.martin@cbrands.com
Patty Yahn-Urlaub 585-678-7483 / patty.yahn-urlaub@cbrands.com
Marisa Pepelea 312-741-2316 / marisa.pepelea@cbrands.com

A PDF containing our Third Quarter Fiscal Year 2021 Results and full financial tables is available at: http://ml.globenewswire.com/Resource/Download/c8c4abee-e476-40cd-95a1-187b23914338

 

ePac Flexible Packaging Extends Global Footprint into Seoul, South Korea

All digital flexible packaging specialist adds second location in Asia Pacific Region

Jakarta, Indonesia, Jan. 06, 2021 (GLOBE NEWSWIRE) — ePac Flexible Packaging, the global leader in digitally produced flexible packaging,  is pleased to announce its intent to open ePac Seoul, Ltd. as the flexible packaging provider expands its network of production plants in the Asia Pacific region. The company’s affiliate, ePac Holdings Asia, will be the managing entity for this, and all future expansion in the region. ePac was established in 2016 in the US, and today operates 18 manufacturing plants across the US, Canada, Europe, and Indonesia.

ePac Seoul, Ltd. is now open for order taking and will be located at 3F, Building C, 195-20, Jayumuyeok-gil, Baeksan-myeon, Gimje-si, Jeollabuk-do, Republic of South Korea 3F, Building C, 195-20, Jayumuyeok-gil, Baeksan-myeon, Gimje-si, Jeollabuk-do, Republic of Korea 54325, which is about 90 minutes outside of Seoul.

ePac Seoul, Ltd. is a partnership between ePac Holdings, ePac Holdings Asia, and  South Korea based CC Labs. Managing the operation will be Mr. Kim Min-Choel. Mr. Kim has served in executive positions with Sejoong Industry and as CEO of CC Labs. With past experience in flexible packaging and digital printing, Mr. Kim is keen to bring ePac’s service delivery model to South Korea, beginning with ePac Seoul.

According to Mr. Kim:“ With small and medium-sized businesses accounting for 99% of all South Koren enterprises, 89% of employment, and strong government support, we’re excited to enter this market. ePac offers game-changing flexible packaging for brands that previously had limited options for sourcing their packaging. Our customers will no longer be limited to importing their packaging, purchasing far more than they need, or applying labels to blank pouches. Our focus is on helping small brands grow with great packaging and our customers’ products stand out on retail shelves and portray an impressive image on e-commerce sites.”

ePac is the industry leader in digitally printed flexible packaging, serving brands of all sizes, but in particular small and medium-sized enterprises. With a value proposition of 10-15 day turnaround, specialization in short and medium run length orders, and the elimination of plates, brands can now order to demand and avoid costly inventory and obsolescence. Built on breakthrough digital printing technology from Hewlett Packard (HP, Inc), ePac offers customizable finished pouches and roll stock with photo-quality graphics, enabling all brands to go to market faster and to rapidly make changes to packaging design.

Added Jack Knott, ePac’s CEO: “ South Korea is an advanced country technologically, and local brands will benefit greatly from our all-digital flexible packaging manufacturing platform. In addition, QR code scan rates are among the highest in the world, so our smart packaging solution, ePacConnect, will provide brands new solutions for engaging with consumers, protecting their brand, and gaining new market insights.”

About ePac Flexible Packaging

As the leading full-service provider of multiple types of flexible pouches and roll stock for small-to-medium-sized brands, ePac provides a sustainable, integrated approach with fast time to market and the highest quality, digitally printed packaging.

Formed in 2016, ePac’s founders began with a mission to provide locally-based consumer packaged goods companies the ability to compete with large brands with great packaging. ePac’s customers are predominantly locally-based small and medium-sized CPGs, many of whom are focused on creating natural and innovative products for their consumers.

In 2020 ePac Holdings Asia was established to manage the company’s growth in the Asia-Pacific region.

For more information, please visit​ http://epacflexibles.kr

Attachment

Carl Joachim
ePac Flexible Packaging
cjoachim@ePacFlexibles.com

Kim Min-Choel
ePac Seoul
mkim@ePacFlexibles.com

ePac Flexible Packaging Extends Global Footprint into Seoul, South Korea

All digital flexible packaging specialist adds second location in Asia Pacific Region

Jakarta, Indonesia, Jan. 06, 2021 (GLOBE NEWSWIRE) — ePac Flexible Packaging, the global leader in digitally produced flexible packaging,  is pleased to announce its intent to open ePac Seoul, Ltd. as the flexible packaging provider expands its network of production plants in the Asia Pacific region. The company’s affiliate, ePac Holdings Asia, will be the managing entity for this, and all future expansion in the region. ePac was established in 2016 in the US, and today operates 18 manufacturing plants across the US, Canada, Europe, and Indonesia.

ePac Seoul, Ltd. is now open for order taking and will be located at 3F, Building C, 195-20, Jayumuyeok-gil, Baeksan-myeon, Gimje-si, Jeollabuk-do, Republic of South Korea 3F, Building C, 195-20, Jayumuyeok-gil, Baeksan-myeon, Gimje-si, Jeollabuk-do, Republic of Korea 54325, which is about 90 minutes outside of Seoul.

ePac Seoul, Ltd. is a partnership between ePac Holdings, ePac Holdings Asia, and  South Korea based CC Labs. Managing the operation will be Mr. Kim Min-Choel. Mr. Kim has served in executive positions with Sejoong Industry and as CEO of CC Labs. With past experience in flexible packaging and digital printing, Mr. Kim is keen to bring ePac’s service delivery model to South Korea, beginning with ePac Seoul.

According to Mr. Kim:“ With small and medium-sized businesses accounting for 99% of all South Koren enterprises, 89% of employment, and strong government support, we’re excited to enter this market. ePac offers game-changing flexible packaging for brands that previously had limited options for sourcing their packaging. Our customers will no longer be limited to importing their packaging, purchasing far more than they need, or applying labels to blank pouches. Our focus is on helping small brands grow with great packaging and our customers’ products stand out on retail shelves and portray an impressive image on e-commerce sites.”

ePac is the industry leader in digitally printed flexible packaging, serving brands of all sizes, but in particular small and medium-sized enterprises. With a value proposition of 10-15 day turnaround, specialization in short and medium run length orders, and the elimination of plates, brands can now order to demand and avoid costly inventory and obsolescence. Built on breakthrough digital printing technology from Hewlett Packard (HP, Inc), ePac offers customizable finished pouches and roll stock with photo-quality graphics, enabling all brands to go to market faster and to rapidly make changes to packaging design.

Added Jack Knott, ePac’s CEO: “ South Korea is an advanced country technologically, and local brands will benefit greatly from our all-digital flexible packaging manufacturing platform. In addition, QR code scan rates are among the highest in the world, so our smart packaging solution, ePacConnect, will provide brands new solutions for engaging with consumers, protecting their brand, and gaining new market insights.”

About ePac Flexible Packaging

As the leading full-service provider of multiple types of flexible pouches and roll stock for small-to-medium-sized brands, ePac provides a sustainable, integrated approach with fast time to market and the highest quality, digitally printed packaging.

Formed in 2016, ePac’s founders began with a mission to provide locally-based consumer packaged goods companies the ability to compete with large brands with great packaging. ePac’s customers are predominantly locally-based small and medium-sized CPGs, many of whom are focused on creating natural and innovative products for their consumers.

In 2020 ePac Holdings Asia was established to manage the company’s growth in the Asia-Pacific region.

For more information, please visit​ http://epacflexibles.kr

Attachment

Carl Joachim
ePac Flexible Packaging
cjoachim@ePacFlexibles.com

Kim Min-Choel
ePac Seoul
mkim@ePacFlexibles.com

Peptomyc Board of Directors appoints Giacomo Di Nepi as Chairman of the Board

Giacomo Di Nepi

Giacomo Di Nepi assumes the role of Chairman of the Board at Peptomyc S.L.

BARCELONA, Spain, Jan. 07, 2021 (GLOBE NEWSWIRE) — Peptomyc S.L., a biotech company specialized in the development of protein and peptide therapeutics targeting the Myc oncoprotein for cancer treatment, announces today that has appointed veteran pharma and biotech executive Giacomo Di Nepi as Chairman of the Board.

Mr. Di Nepi has accumulated nearly 40 years of global experience in the Healthcare sector. His career started with 16 years at McKinsey & Company, where he was a Partner and Core Leadership member of the Global Pharmaceutical Practice, followed by 11 years at Novartis where he held a number of executive roles, including CEO of Novartis Italy and Global Head of the Infectious Diseases, Transplantation and Immunology Global Business Unit and member of the Global Pharma Executive Committee. He subsequently served as CEO of Takeda Europe starting in 2006. In 2009, he started and substantially grew the European operations of InterMune, and launched the blockbuster rare disease product Esbriet® (pirfenidone), until InterMune purchase for USD 8.3bn and integration with Roche in 2015. Then, in 2016, Mr. Di Nepi became CEO of Polyphor in Switzerland and led the company bringing two products to Phase III and successfully raising over CHF 200m – including a CHF 155m IPO, which was the largest primary biotech IPO in Switzerland in the previous 10 years. He was recently appointed as Senior Advisor for Health Care Private Equity in Europe by KKR and is a Non-Executive Director at Geneuro, NTC and Zambon. He is also an advisor to Handicap International.

Laura Soucek, CEO of Peptomyc, says: “We are delighted to have Giacomo joining us. His impressive track record in the Healthcare sector, together with his experience in different executive and Board roles at some of the most prestigious pharma and biotech companies worldwide, represent a huge new asset for our company. I am confident that Giacomo will significantly contribute to the success of our project and bring a new and valuable point of view to the table.”

“I am extremely happy and honored to join Peptomyc”, said Giacomo Di Nepi. “I believe Peptomyc has a strong team and a breakthrough technology that could provide a radical innovation in oncology, and deliver major therapeutic benefit to the patients suffering from several types of cancer and substantial and sustained value creation to its shareholders. This is a particularly exciting moment to join the company, as it is now entering the clinical stage with its lead compound, OMO103 – with the first patient expected to be recruited in a Phase I/II trial in Q1 2021.”

About Peptomyc

Peptomyc (www.peptomyc.com) is a spin-off from VHIO – the Vall d’Hebron Institute of Oncology – and ICREA – the Catalan Institute of Research and Advanced Studies –, founded in December 2014 in Barcelona, Spain. The company is focused on the development of innovative cell penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment.

PEPTOMYC S.L.
Office email: info@peptomyc.com
Centre CELLEX – C/ Natzaret, 115-117 – Barcelona, Spain, 08035

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/981f8e74-2725-4f03-9e01-c079aeaeb0bd

Peptomyc Board of Directors appoints Giacomo Di Nepi as Chairman of the Board

Giacomo Di Nepi

Giacomo Di Nepi assumes the role of Chairman of the Board at Peptomyc S.L.

BARCELONA, Spain, Jan. 07, 2021 (GLOBE NEWSWIRE) — Peptomyc S.L., a biotech company specialized in the development of protein and peptide therapeutics targeting the Myc oncoprotein for cancer treatment, announces today that has appointed veteran pharma and biotech executive Giacomo Di Nepi as Chairman of the Board.

Mr. Di Nepi has accumulated nearly 40 years of global experience in the Healthcare sector. His career started with 16 years at McKinsey & Company, where he was a Partner and Core Leadership member of the Global Pharmaceutical Practice, followed by 11 years at Novartis where he held a number of executive roles, including CEO of Novartis Italy and Global Head of the Infectious Diseases, Transplantation and Immunology Global Business Unit and member of the Global Pharma Executive Committee. He subsequently served as CEO of Takeda Europe starting in 2006. In 2009, he started and substantially grew the European operations of InterMune, and launched the blockbuster rare disease product Esbriet® (pirfenidone), until InterMune purchase for USD 8.3bn and integration with Roche in 2015. Then, in 2016, Mr. Di Nepi became CEO of Polyphor in Switzerland and led the company bringing two products to Phase III and successfully raising over CHF 200m – including a CHF 155m IPO, which was the largest primary biotech IPO in Switzerland in the previous 10 years. He was recently appointed as Senior Advisor for Health Care Private Equity in Europe by KKR and is a Non-Executive Director at Geneuro, NTC and Zambon. He is also an advisor to Handicap International.

Laura Soucek, CEO of Peptomyc, says: “We are delighted to have Giacomo joining us. His impressive track record in the Healthcare sector, together with his experience in different executive and Board roles at some of the most prestigious pharma and biotech companies worldwide, represent a huge new asset for our company. I am confident that Giacomo will significantly contribute to the success of our project and bring a new and valuable point of view to the table.”

“I am extremely happy and honored to join Peptomyc”, said Giacomo Di Nepi. “I believe Peptomyc has a strong team and a breakthrough technology that could provide a radical innovation in oncology, and deliver major therapeutic benefit to the patients suffering from several types of cancer and substantial and sustained value creation to its shareholders. This is a particularly exciting moment to join the company, as it is now entering the clinical stage with its lead compound, OMO103 – with the first patient expected to be recruited in a Phase I/II trial in Q1 2021.”

About Peptomyc

Peptomyc (www.peptomyc.com) is a spin-off from VHIO – the Vall d’Hebron Institute of Oncology – and ICREA – the Catalan Institute of Research and Advanced Studies –, founded in December 2014 in Barcelona, Spain. The company is focused on the development of innovative cell penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment.

PEPTOMYC S.L.
Office email: info@peptomyc.com
Centre CELLEX – C/ Natzaret, 115-117 – Barcelona, Spain, 08035

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/981f8e74-2725-4f03-9e01-c079aeaeb0bd

COVID Cases Rise in Israel Despite Successful Vaccine Rollout

JERUSALEM – Israel is the world leader in number of COVID-19 vaccinations per person, with 15 percent of the population already vaccinated. At the same time, the number of coronavirus infections is spiraling and Israel is going into another tight lockdown.

As of midnight on Thursday, all schools and nonessential businesses will close down, all gatherings will be outlawed, and Israelis are supposed to stay home for at least two weeks to try to get the numbers of new COVID-19 cases down. Shlomi Codish is the director General of the Soroka hospital in the southern Israeli city of Beersheva.

“Regretfully we’re seeing a surge in patients that is beyond what we saw in the previous wave of COVID-19 illness. We’re currently seeing 7,000 new patients daily, over that, we’re performing a lot of tests, a lot of vaccinations, but we’re seeing a lot of seriously ill patients,” said Codish. “We’re currently at 873 critically sick patients nationwide which is a number that is considered around the threshold of the health care system capacity.”

This is the third time that Israel has gone to a lockdown since the COVID-19 crisis began last March. In previous times, various sectors of the population ignored the rules. Ultra-Orthodox Jews kept their religious schools open, and many among the Arab population continued to hold large weddings.

This time, the wedding season is over, and influential ultra-Orthodox rabbis have called for schools to close at least for a few days. Shlomi Codish from Soroka hospital believes Israel could have avoided this total lockdown.

“If we had better public trust, better understanding of what the deal really is here, we would have been able to implement less strict measures two or three weeks ago,” said Codish. “Regretfully we’re now at a point where disease patterns are spiraling out of control and we need to fully lock down the Israeli public activity altogether.”

Israeli Prime Minister Benjamin Netanyahu has promised that Israel will be the first country to beat the coronavirus and reopen the economy.

Israel rolled out a vaccination program less than three weeks ago that has seen more than one-point-five million Israelis, most of them over 60 or with chronic conditions, vaccinated.

Part of the reason the government was able to move so fast is that every Israeli is a member of one of four health insurance plans that keep computerized medical records. Israel is also a small country with just over nine million people.

Israeli press reports say that Israel has paid Pfizer about $30 per dose, significantly more than other countries, to ensure millions of doses of its vaccine. Israel is also expected to get the Moderna vaccine in the coming days.

Two weeks after receiving their second dose of the vaccine, Israelis will get a green passport that will enable them to travel freely, avoid quarantine when returning from abroad, and participate in cultural events.

Source: Voice Of America

Boeing Will Pay $2.5 Billion to Settle Charge Over Plane

Boeing will pay $2.5 billion to settle a criminal conspiracy charge for misleading regulators about the safety of its 737 Max aircraft, which suffered two deadly crashes shortly after entering airline service.

The Justice Department said Thursday that Boeing agreed to the settlement, which includes money for the crash victims’ families, airline customers and a criminal fine.

Prosecutors said Boeing employees concealed important information about the plane from the Federal Aviation Administration (FAA), then covered up their actions.

“The misleading statements, half-truths and omissions communicated by Boeing employees to the FAA impeded the government’s ability to ensure the safety of the flying public,” said Erin Nealy Cox, the U.S. attorney in Dallas.

“Boeing’s employees chose the path of profit over candor,” said David Burns, acting assistant attorney general for the Justice Department’s criminal division.

‘Right thing for us to do’

Boeing CEO David Calhoun said settling the charge “is the right thing for us to do — a step that appropriately acknowledges how we fell short of our values and expectations.” He said it would remind Boeing employees to be transparent with regulators.

The government will drop the criminal charge after three years if Boeing follows the terms of the settlement.

Boeing began working on the Max in 2011 as an answer to a new, more fuel-efficient model from European rival Airbus. Boeing admitted in court filings that two of its technical pilot experts deceived the FAA about a flight-control system called the Maneuvering Characteristics Augmentation System, or MCAS, that could point a plane’s nose down if sensors indicated the plane might be in danger of an aerodynamic stall — that it might fall from the sky.

Boeing downplayed the significance of MCAS and did not mention it in airplane manuals. Most pilots did not know about it.

The first airlines began flying the 737 Max in mid-2017. On October 29, 2018, a Max operated by Indonesia’s Lion Air plunged into the Java Sea. The FAA let the Max keep flying, and on March 10, 2019, another Max operated by Ethiopian Airlines crashed nearly straight down into a field. In all, 346 people were killed.

On both flights, MCAS was activated by a faulty reading from a single sensor. The system repeatedly pushed the planes’ noses down, and pilots were unable to regain control.

After the planes were grounded worldwide, Boeing changed MCAS so that it always uses two sensors, along with other changes to make the automated system less powerful and easier for pilots to override. The FAA ordered other changes, including the rerouting of some wiring to avoid potential dangerous short-circuiting.

In November, the FAA approved Boeing’s changes, and several carriers, including American Airlines, have resumed using the planes.

$500 million for families of passengers

Under the settlement announced Thursday, Boeing will pay a $243.6 million fine, $1.77 billion in compensation to airlines that were unable to use their Max jets while they were grounded, and $500 million into a fund for the families of passengers who were killed in the crashes.

Boeing said in a regulatory filing that it will take a $743.6 million charge against earnings because of the settlement.

The crashes and grounding of the Max, Boeing’s best-selling plane, has plunged the Chicago-based company into its deepest crisis. It has led to billions in losses and resulted in the ouster of former CEO Dennis Muilenburg in December 2019.

Source: Voice Of America